Ars Technica coverage: Supreme Court saves medical profession from diagnostic patents.
Archive for Science
Religion requires faith. Science requires trust. Trust is earned and subject to revision, faith is not.
So last December the Danish had something on the order of 150 heads of state in Copenhagen for the failed climate talks. I wonder how much the security bill for that was.
“Bringing together traditional and modern medicine faces numerous challenges that stem from differences in how each is practiced, evaluated and managed. What are researchers doing to bridge the gap?”
Pigs Fly: Federal Court Invalidates Myriad’s Patent Claims
Boo. Also, Yah.
1. The Plaintiffs Win. The ruling appears to be a nearly complete victory for the plaintiffs and their supporters, including the ACLU. With respect to Myriad’s issued patents on the BRCA1 and BRCA2 genes, Judge Sweet’s ruling invalidates both Myriad’s composition of matter claims (its patents on isolated DNA sequences to all or a portion of the breast cancer genes) and its method claims (those patent claims that relate to analyzing or comparing isolated DNA sequences in order to detect mutations in a patient’s BRCA1/2 genes that might cause breast cancer).
The overall tone of the Court’s ruling is best captured by this passage (from page 135):
The identification of the BRCA1 and BRCA2 gene sequences is unquestionably a valuable scientific achievement for which Myriad deserves recognition, but that is not the same as concluding that it is something for which they are entitled to a patent.
Instead of super-cooling the material, as is necessary for conventional superconductors, the new material is instead super-compressed. The researchers claim that the new material could sidestep the cooling requirement, thereby enabling superconducting wires that work at room temperature.
Nice. Continually cited as the holy grail in superconductor research. We’ll see what happens but is good to see continuous improvement in basic materials science.